Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Gap19: Selective Connexin 43 Hemichannel Blocker for Neur...

    2026-01-22

    Gap19: Selective Connexin 43 Hemichannel Blocker for Neuroprotection and Inflammation Research

    Executive Summary: Gap19 is a short peptide derived from the intracellular cytoplasmic loop of connexin 43 (Cx43), acting as a highly selective Cx43 hemichannel inhibitor (IC50 ≈ 50 μM) without affecting gap junction channels (Gap26.com article). It blocks ATP release in astrocytes in a dose-dependent manner, with an IC50 of 142 μM, critical for modulating neuroglial interactions (Wu et al., 2020). Gap19 demonstrates in vivo neuroprotection in mouse stroke models, especially when administered at 300 μg/kg intracerebroventricularly or as a TAT-conjugate at 25 mg/kg intraperitoneally. The peptide is supplied as a solid (MW 1161.45, C55H96N14O13), water-soluble (≥58.07 mg/mL), and stable at -20°C for short-term use (APExBIO product page). Benchmarks support its use in dissecting Cx43-dependent signaling pathways in stroke, ischemia/reperfusion, and immune modulation (2-fma.com).

    Biological Rationale

    Connexin 43 (Cx43) forms both gap junction channels and hemichannels in astrocytes and macrophages, playing a pivotal role in cell-cell communication, ATP release, and neuroimmune regulation (Wu et al., 2020). Dysregulated Cx43 hemichannel activity is implicated in neuroinflammatory and ischemic injury pathways. Selective blockade of Cx43 hemichannels without disrupting gap junctional communication is essential for dissecting their distinct roles in neuroglial and immune interactions (Gap26.com article). Gap19 fills this need as a highly specific Cx43 hemichannel inhibitor peptide, enabling targeted modulation of ATP release and downstream signaling in both neural and immune contexts (Gap26.com article).

    Mechanism of Action of Gap19

    Gap19 is derived from the cytoplasmic loop domain (residues 128-136) of Cx43, targeting the intracellular interaction required for hemichannel opening (APExBIO). It selectively inhibits Cx43 hemichannel currents at an IC50 of approximately 50 μM, sparing gap junction channels even at higher concentrations. This selectivity is attributed to the peptide's ability to disrupt the cytoplasmic loop–C-terminal domain interaction, a mechanism unique to hemichannels (JIB-04.com article). In cultured cortical astrocytes, Gap19 reduces ATP release in a dose-dependent manner (IC50 = 142 μM), implicating its role in modulating neuroglial and immune cell signaling. In vivo, Gap19 confers neuroprotection by diminishing neuronal damage and infarct volume in ischemic mouse models, with evidence for JAK2/STAT3 pathway involvement when administered as a TAT-conjugate post-reperfusion (Wu et al., 2020).

    Evidence & Benchmarks

    • Gap19 inhibits Cx43 hemichannel currents with an IC50 ≈ 50 μM in patch-clamp studies, without affecting gap junction channels (https://www.apexbt.com/gap19.html).
    • ATP release from cultured cortical astrocytes is reduced by Gap19 in a dose-dependent manner (IC50 = 142 μM), confirming selective hemichannel inhibition (https://doi.org/10.3892/mmr.2020.11023).
    • In a mouse model of middle cerebral artery occlusion, intracerebroventricular administration of Gap19 (300 μg/kg) reduces infarct volume and neurological deficits (https://doi.org/10.3892/mmr.2020.11023).
    • TAT-conjugated Gap19, administered intraperitoneally at 25 mg/kg 4h post-reperfusion, provides significant neuroprotection and modulates the JAK2/STAT3 pathway (https://doi.org/10.3892/mmr.2020.11023).
    • Gap19 and related Cx43 inhibitors suppress Angiotensin II-induced RAW264.7 macrophage polarization toward the M1 phenotype by inhibiting Cx43/NF-κB signaling (https://doi.org/10.3892/mmr.2020.11023).

    This article extends prior reviews (e.g., Gap26.com #99) by systematically benchmarking in vitro and in vivo selectivity and highlighting translational applicability in ischemia-reperfusion research.

    Applications, Limits & Misconceptions

    Applications:

    • Dissection of Cx43 hemichannel roles in neuroglial signaling and ATP-mediated neuroimmune modulation (Gap26.com #24).
    • Neuroprotection studies in ischemia/reperfusion injury and stroke models, with robust evidence for infarct and deficit reduction.
    • Characterization of immune cell polarization (e.g., macrophage M1/M2 status) via Cx43/NF-κB pathway modulation.
    • Pharmacological interrogation of the JAK2/STAT3 signaling axis in neuroimmune tissues.

    Common Pitfalls or Misconceptions

    • Gap19 does not block Cx43 gap junction channels; its action is specific to hemichannels (APExBIO).
    • Gap19 is not effective against hemichannels formed by other connexin isoforms (e.g., Cx40, Cx32).
    • Peptide is unstable at room temperature or in solution for extended periods; store at -20°C and use solutions promptly.
    • Insoluble in ethanol; dissolution should be performed in water or DMSO as per solubility data.
    • Systemic delivery requires TAT-conjugation for blood-brain barrier permeability.

    For more on experimental workflow optimization and troubleshooting, see this article, which focuses on practical laboratory integration, whereas the current review details molecular selectivity and translational endpoints.

    Workflow Integration & Parameters

    • Formulation: Gap19 is supplied as a solid (MW 1161.45, C55H96N14O13); reconstitute in sterile water (≥58.07 mg/mL) or DMSO (≥26.55 mg/mL).
    • Storage: Store lyophilized peptide at -20°C; prepared solutions are for short-term use only.
    • Recommended dosing: In vitro: 50–150 μM for hemichannel inhibition in cell culture. In vivo: 300 μg/kg (ICV), 25 mg/kg (IP, TAT-conjugated).
    • Controls: Always include vehicle and, where possible, Cx43 gap junction channel-specific controls to confirm selectivity.
    • Regulatory note: For research use only. Not for human or clinical therapeutic application.

    For validated protocols and reproducibility guidance, this resource addresses assay optimization and selectivity benchmarking, complementing the mechanistic focus here.

    Conclusion & Outlook

    Gap19 (SKU B4919, APExBIO) is a rigorously validated, selective Cx43 hemichannel inhibitor peptide. It enables precise modulation of neuroglial and immune signaling without impacting gap junction channel function. In stroke and ischemia models, Gap19 confers reproducible neuroprotection and reveals novel insights into Cx43–mediated pathways, including modulation of the JAK2/STAT3 axis. As interest in connexin-targeted therapeutics grows, Gap19 is poised to support mechanistic and translational studies in neuroprotection, inflammation, and immune regulation. For detailed workflows and up-to-date benchmarks, consult supplementary resources and interlinked articles cited above.